Abstract
Although multiparameter flow cytometry (MFC) has demonstrated clinical relevance in monoclonal gammopathy of undetermined significance (MGUS)/myeloma, immunophenotypic studies on the full spectrum of Waldenström’s Macroglobulinemia (WM) remain scanty. Herein, a comprehensive MFC analysis on bone marrow samples from 244 newly diagnosed patients with an immunoglobulin M (IgM) monoclonal protein was performed, including 67 IgM-MGUS, 77 smoldering and 100 symptomatic WM. Our results show a progressive increase on the number and light-chain-isotype-positive B-cells from IgM-MGUS to smoldering and symptomatic WM (P<.001), with only 1% of IgM-MGUS patients showing >10% B cells or 100% light-chain-isotype-positive B-cells (P<.001). Complete light-chain restriction of the B-cell compartment was an independent prognostic factor for time-to progression in smoldering WM (median 26 months; HR: 19.8, P=0.001) and overall survival in symptomatic WM (median 44 months; HR: 2.6, P=0.004). The progressive accumulation of light-chain-isotype-positive B-cells accompanied the emergence of a characteristic Waldenstrom’s phenotype (CD22+dim/CD25+/CD27+/IgM+) that differed from other B-NHL by negative expression of CD5, CD10, CD11c or CD103. In contrast to myeloma, light-chain-isotype-positive plasma cells in IgM monoclonal gammopathies show otherwise normal antigenic expression. Our results highlight the potential value of MFC immunophenotyping for the characterization of the Waldenström’s clone, as well as for the differential diagnosis, risk of progression and survival in WM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Swerdlow S, Campos E, Harris N, Jaffe E, Pileri S, Stein H et al WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.
Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110–115.
Gertz MA . Waldenstrom macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 503–510.
Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, Kumar S et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012; 119: 4462–4466.
Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102: 3759–3764.
Kyle RA, Rajkumar SV . Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3–9.
Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM . A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418–5422.
Kyle RA, Benson J, Larson D, Therneau T, Dispenzieri A, Melton Iii LJ et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2009; 9: 17–18.
Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564–569.
McMaster ML, Caporaso N . Waldenstrom macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition. Br J Haematol 2007; 139: 663–671.
Schop RF, Van Wier SA, Xu R, Ghobrial I, Ahmann GJ, Greipp PR et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006; 169: 150–153.
Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005; 23: 4662–4668.
Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M . Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18: 214–226.
van Dongen JJ, Orfao A . EuroFlow: resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia 2012; 26: 1899–1907.
Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586–2592.
Paiva B, Vidriales MB, Mateo G, Perez JJ, Montalban MA, Sureda A et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009; 114: 4369–4372.
San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guijo F, Sanchez ML et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 187–195.
Ocio EM, Hernandez JM, Mateo G, Sanchez ML, Gonzalez B, Vidriales B et al. Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma. Clin Lymphoma 2005; 5: 241–245.
Howard MT, Hodnefield J, Morice WG . Immunohistochemical phenotyping of plasma cells in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia is comparable to flow cytometric techniques. Clin Lymphoma Myeloma Leuk 2011; 11: 96–98.
Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P . Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol 2005; 124: 414–420.
Merli M, Arcaini L, Boveri E, Rattotti S, Picone C, Passamonti F et al. Assessment of bone marrow involvement in non-Hodgkin’s lymphomas: comparison between histology and flow cytometry. Eur J Haematol 2010; 85: 405–415.
Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED . Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia. Mod Pathol 2009; 22: 807–816.
Remstein ED, Hanson CA, Kyle RA, Hodnefield JM, Kurtin PJ . Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom’s macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol 2003; 30: 182–186.
Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003; 30: 116–120.
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012; 367: 826–833.
Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117: 4701–4705.
Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152: 1655–1665.
Landgren O, Staudt L . MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012; 367: 2255–2257.
Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms. Blood 2013; 121: 2522–2528.
Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X et al. MYD88 L265P in Waldenström's macroglobulinemia, IgM monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific PCR. Blood 2013; 121: 2051–2058.
Garcia-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115: 575–582.
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113: 4163–4170.
Paiva B, Vidriales MB, Perez JJ, Lopez-Berges MC, Garcia-Sanz R, Ocio EM et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood 2011; 117: 3613–3616.
Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692–1700.
Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV . Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2012; 27: 941–946.
Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2012; 27: 208–212.
Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115–119.
Pasqualucci L, Trifonov V, Fabbri G . Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43: 830–837.
Puente X, Pinol M, Quesada V . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 470: 101–105.
Perez-Andres M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 2010; 78 (Suppl 1): S47–S60.
Owen R, Feyler S, O'Connor S, Bond L, De Tute R, Rawstron A . Defining IgM multiple myeloma. Am J Hematol 2011, 717.
Pasricha SR, Juneja SK, Westerman DA, Came NA . Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia. J Clin Pathol 2011; 64: 520–523.
Acknowledgements
This work was supported by the Cooperative Research Thematic Network (RTICC) RD06/0020/0006, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897/01370) and Consejería de Sanidad, Junta de Castilla y León, Valladolid, Spain (557/A/10).
Author contributions
JFSM and BP conceived the idea and together with RGS, EMO, AO and MBV designed the study protocol; BP, MCM, JJP and MBV analyzed the flow cytometry data; RGS, EMO, JA, NdH, FE, RC, AGdC, JG, JH, MS, AM, EP, AB, JA, LS, TJGL and JFSM contributed with provision of study material or patients; BP and JFSM analyzed and interpreted data; BP performed statistical analysis; BP and JFSM wrote the manuscript. All authors reviewed and approved the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Paiva, B., Montes, M., García-Sanz, R. et al. Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia 28, 166–173 (2014). https://doi.org/10.1038/leu.2013.124
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.124
Keywords
This article is cited by
-
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
Leukemia (2023)
-
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study
Blood Cancer Journal (2023)
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia (2019)
-
Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study
Annals of Hematology (2018)
-
From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation
Blood Cancer Journal (2017)